

55
44

ABSTRACT OF THE DISCLOSURE

Peptide-like compounds and their variants having immunomodulating activity including the N-terminal acylated and/or C-terminal amidated or esterified forms thereof of up to 60
5 amino acids wherein the peptide-type compound comprises the formula:

α - β

wherein:

α and β are the same or different and are of the formula:

(a) $\{R\ aa^{76-77} L\} (aa^{79-84})$

10

or

(b) $(aa^{84-79}) \{L\ aa^{77-76} R\}$

wherein:

aa^{76} is E or V;

aa^{77} is D, S or N;

15

aa^{79} is R or G;

aa^{80} is I or N;

aa^{81} is a hydrophobic or small amino acid;

aa^{82} is R or L;

aa^{83} is G or R;

20

aa^{84} is a hydrophobic or small amino acid;

wherein

the sequence in the brackets may optionally be absent or truncated at any peptide type bond within the brackets may be used by themselves or in combination with immunosuppressant drugs, to reduce CTL activation, particularly in association with
25 transplantation.